News and advice from an investor-CEO, with Milenko Cicmil

LSX World Congress is a meeting place for biotechs, big pharma companies, and investors. Milenko Cicmil is familiar with all three worlds as CEO of Tasca Therapeutics, an investor with Cure Ventures, and a past career that includes stints at AstraZeneca, MSD, and Ipsen.

Editor-in-chief Jonah Comstock caught up with Cicmil to talk about Tasca Therapeutics’ news at the show: their first patient dosed for lead asset CP-383, a small molecule designed to modulate a novel oncogenic signaling pathway that could have potential in a variety of cancers and even have implications beyond oncology.

Cicmil also puts on his investor hat to give some tips for startups about thinking early about manufacturing, licensing, and royalties, and thinking critically about funding raises. Check out the interview to here words of wisdom from a man of broad pharma experience, as well as more about the exciting work happening at Tasca.